Lessons from Anti-Amyloid- β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target

Conclusions: Despite the overall disappointing results, there is still hope that A β immunotherapy in presymptomatic patients will prevent neuronal loss and provide significant clinical benefits that can be applied to larger populations as preventive therapies. Advances with other targets may soon provide additional therapeutic options for AD with increased efficacy.Neurodegener Dis 2017;17:242-250
Source: Neurodegenerative Diseases - Category: Neurology Source Type: research